Avedro, EyeGate Pharma to enter agreement

EyeGate Pharma’s broad iontophoresis patent portfolio for corneal collagen cross-linking will be held as exclusive license by Avedro Inc. Delivery approach provides potential additional benefits to current formulation.

Related Videos

Related Content

Advertisement

March 15th 2025

ARVO announces Swathi Kaliki, MD, as recipient of 2025 Ludwig von Sallmann Clinician-Scientist Award

December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

March 14th 2025

Survey reveals gaps in patient awareness of preservative-free glaucoma treatments

November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

March 13th 2025

Harrow to enact a 5-year strategic supply and development agreement for triamcinolone acetonide injectable suspension

March 12th 2025

Tenpoint Therapeutics Ltd. appoints Carol Kearney as Chief Commercial Officer

Related Content

Advertisement

March 15th 2025

ARVO announces Swathi Kaliki, MD, as recipient of 2025 Ludwig von Sallmann Clinician-Scientist Award

December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

March 14th 2025

Survey reveals gaps in patient awareness of preservative-free glaucoma treatments

November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

March 13th 2025

Harrow to enact a 5-year strategic supply and development agreement for triamcinolone acetonide injectable suspension

March 12th 2025

Tenpoint Therapeutics Ltd. appoints Carol Kearney as Chief Commercial Officer